This site is intended for healthcare professionals

The Lancet publishes results from phase III induction and maintenance programs evaluating Rinvoq in ulcerative colitis.- AbbVie

Read time: 1 mins
Published:2nd Jun 2022

AbbVie announced The Lancet published results from three pivotal Phase III clinical trials – U-ACHIEVE (induction), U-ACCOMPLISH and U-ACHIEVE (maintenance) – evaluating upadacitinib (Rinvoq) in patients with moderately to severely active ulcerative colitis who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.


Data from the three studies formed the basis of the company's application for approval by regulatory agencies. The publication reports the efficacy and safety results of the two induction studies and a maintenance study evaluating clinical remission and endoscopic improvement with oral upadacitinib versus placebo over 8 weeks and 52 weeks, respectively.

The use of upadacitinib for ulcerative colitis is not approved in the European Union and its safety and efficacy remain under review by the global health authorities.

See- "Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase III, multicentre, double-blind, randomised trials."_ The Lancet Published: May 26, 2022 Silvio Danese,Séverine Vermeire,Wen Zhou, Aileen L Pangan, Jesse Siffledeen,Susan Greenbloom,and others.

Condition: Ulcerative Colitis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.